Net Worth Advisory Group Purchases New Stake in Amgen Inc. $AMGN

Net Worth Advisory Group acquired a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 2,538 shares of the medical research company’s stock, valued at approximately $831,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Board of the Pension Protection Fund bought a new position in shares of Amgen in the 4th quarter valued at about $26,000. Olistico Wealth LLC bought a new stake in shares of Amgen during the fourth quarter worth approximately $33,000. Holos Integrated Wealth LLC acquired a new position in Amgen in the fourth quarter valued at approximately $37,000. Howard Hughes Medical Institute acquired a new position in Amgen in the second quarter valued at approximately $32,000. Finally, Cloud Capital Management LLC bought a new position in Amgen in the third quarter valued at approximately $34,000. 76.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Rothschild & Co Redburn lifted their target price on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Argus raised their price target on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Citigroup lifted their price objective on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Oppenheimer set a $400.00 price objective on Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Finally, Guggenheim increased their target price on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $354.60.

Amgen Trading Down 1.2%

AMGN opened at $348.77 on Friday. The firm’s fifty day moving average is $362.59 and its two-hundred day moving average is $329.87. The firm has a market cap of $188.01 billion, a PE ratio of 24.51, a price-to-earnings-growth ratio of 3.50 and a beta of 0.45. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 EPS. The firm’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.